Heparinoids: Difference between revisions
No edit summary |
m Protected "Heparinoids": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Heparinoids''' are [[glycosaminoglycan]]s which are derivatives of [[heparin]]. | '''Heparinoids''' are [[glycosaminoglycan]]s which are derivatives of [[heparin]]. | ||
Line 11: | Line 14: | ||
* {{DiseasesDB|31460}} | * {{DiseasesDB|31460}} | ||
==References== | |||
[[Category:Cardiovascular Drugs]][[Category: | {{reflist|2}} | ||
{{Peripheral vasodilators}} | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] |
Latest revision as of 16:27, 20 August 2015
WikiDoc Resources for Heparinoids |
Articles |
---|
Most recent articles on Heparinoids Most cited articles on Heparinoids |
Media |
Powerpoint slides on Heparinoids |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Heparinoids at Clinical Trials.gov Clinical Trials on Heparinoids at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Heparinoids
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Heparinoids Discussion groups on Heparinoids Patient Handouts on Heparinoids Directions to Hospitals Treating Heparinoids Risk calculators and risk factors for Heparinoids
|
Healthcare Provider Resources |
Causes & Risk Factors for Heparinoids |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Heparinoids are glycosaminoglycans which are derivatives of heparin.
See also
External links
- Heparinoids at the US National Library of Medicine Medical Subject Headings (MeSH)
- Template:DiseasesDB